API | prulifloxacin

prulifloxacin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Prulifloxacin is an older synthetic antibiotic of the fluoroquinolone class undergoing clinical trials prior to a possible NDA submission to the U.S. Food and Drug Administration (FDA). It is a prodrug which is metabolized in the body to the active compound ulifloxacin. It was developed over two decades ago by Nippon Shinyaku Co. and was patented in Japan in 1987 and in the United States in 1989. ^Wikipedia

Chemistry

SMILES: CC1SC2=C(C(=O)O)C(=O)c3cc(F)c(cc3N12)N4CCN(CC5=C(C)OC(=O)O5)CC4
InChIKey: PWNMXPDKBYZCOO-UHFFFAOYSA-N
Mol. Mass: 461.47
ALogP: 2.64 Partition coefficient
ChEMBL Molecule:
prulifloxacin

More Chemistry

Pharmacology

Mechanism of Action:
- DNA gyrase subunit A (Staphylococcus aureus) ^UniProt
- DNA gyrase subunit B (Staphylococcus aureus) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1h,4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-(4-((5-methyl-2-oxo-1,3-dioxol-4-yl)methyl)-1-piperazinyl)-4-oxo- | 6-fluoro-1-methyl-7-(4-(5-methyl-2-oxo-1,3-dioxelen-4-yl)methyl-1-piperazinyl)-4-oxo-4h-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acid | nm441 | nm 441 | nm-441 | prulifloxacin | sea buckthorn | sea buckthorn oil

Organizations (24)

Research & Development (24)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Urinary Tract Infections

Experimental Indications - Clinical Trial Phases 1-4 (6)

Bacterial Infections ()

Bronchitis (Phase 3)

Gastroenteritis (Phase 3)

Prostatitis (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Urinary Tract Infections (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 14
# of Trial Organizations: 24

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue